# A PMS of Jakavi® in Patients With Steroid-Refractory Graft-versus-Host Disease (SR-GvHD) in Korea

> **NCT05621733** · — · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 127 (estimated)

## Conditions studied

- Graft-versus-Host Disease

## Interventions

- **OTHER:** ruxolitinib

## Key facts

- **NCT ID:** NCT05621733
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-07
- **Primary completion:** 2026-05-09
- **Final completion:** 2026-05-09
- **Target enrollment:** 127 (ESTIMATED)
- **Last updated:** 2025-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05621733

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05621733, "A PMS of Jakavi® in Patients With Steroid-Refractory Graft-versus-Host Disease (SR-GvHD) in Korea". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05621733. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*